000127880 001__ 127880
000127880 005__ 20240228135034.0
000127880 0247_ $$2doi$$a10.1002/ijc.28386
000127880 0247_ $$2pmid$$apmid:23852775
000127880 0247_ $$2pmc$$apmc:PMC4232887
000127880 0247_ $$2ISSN$$a0020-7136
000127880 0247_ $$2ISSN$$a1097-0215
000127880 0247_ $$2altmetric$$aaltmetric:1954777
000127880 037__ $$aDKFZ-2017-03902
000127880 041__ $$aeng
000127880 082__ $$a610
000127880 1001_ $$0P:(DE-He78)9c8a10405c0a6ffe7941d65e89cb7c61$$aLacroix, Jeannine Ariane Desiree$$b0$$eFirst author$$udkfz
000127880 245__ $$aOncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis.
000127880 260__ $$aBognor Regis$$bWiley-Liss$$c2014
000127880 3367_ $$2DRIVER$$aarticle
000127880 3367_ $$2DataCite$$aOutput Types/Journal article
000127880 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1506673006_21209
000127880 3367_ $$2BibTeX$$aARTICLE
000127880 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000127880 3367_ $$00$$2EndNote$$aJournal Article
000127880 520__ $$aBased on extensive pre-clinical studies, the oncolytic parvovirus H-1 (H-1PV) is currently applied to patients with recurrent glioblastoma in a phase I/IIa clinical trial (ParvOryx01, NCT01301430). Cure rates of about 40% in pediatric high-risk medulloblastoma (MB) patients also indicate the need of new therapeutic approaches. In order to prepare a future application of oncolytic parvovirotherapy to MB, the present study preclinically evaluates the cytotoxic efficacy of H-1PV on MB cells in vitro and characterizes cellular target genes involved in this effect. Six MB cell lines were analyzed by whole genome oligonucleotide microarrays after treatment and the results were matched to known molecular and cytogenetic risk factors. In contrast to non-transformed infant astrocytes and neurons, in five out of six MB cell lines lytic H-1PV infection and efficient viral replication could be demonstrated. The cytotoxic effects induced by H-1PV were observed at LD50s below 0.05 p. f. u. per cell indicating high susceptibility. Gene expression patterns in the responsive MB cell lines allowed the identification of candidate target genes mediating the cytotoxic effects of H-1PV. H-1PV induced down-regulation of key regulators of early neurogenesis shown to confer poor prognosis in MB such as ZIC1, FOXG1B, MYC, and NFIA. In MB cell lines with genomic amplification of MYC, expression of MYC was the single gene most significantly repressed after H-1PV infection. H-1PV virotherapy may be a promising treatment approach for MB since it targets genes of functional relevance and induces cell death at very low titers of input virus.
000127880 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000127880 588__ $$aDataset connected to CrossRef, PubMed,
000127880 7001_ $$0P:(DE-He78)22e6128f8d5789c3a0c86bb0e5ca54e5$$aSchlund, Franziska$$b1$$udkfz
000127880 7001_ $$0P:(DE-He78)119d7d540a0e6fc5734898bef4866d7f$$aLeuchs, Barbara$$b2$$udkfz
000127880 7001_ $$0P:(DE-HGF)0$$aAdolph, Kathrin$$b3
000127880 7001_ $$0P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aSturm, Dominik$$b4$$udkfz
000127880 7001_ $$0P:(DE-HGF)0$$aBender, Sebastian$$b5
000127880 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b6$$udkfz
000127880 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b7$$udkfz
000127880 7001_ $$0P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aWitt, Olaf$$b8$$udkfz
000127880 7001_ $$0P:(DE-He78)2d7958ea507b0b738619074b38ec6d54$$aRommelaere, Jean$$b9$$udkfz
000127880 7001_ $$0P:(DE-HGF)0$$aSchlehofer, Jörg R$$b10
000127880 7001_ $$0P:(DE-He78)046fd145f1008f83f6236580727bbc0f$$aWitt, Hendrik$$b11$$udkfz
000127880 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.28386$$gVol. 134, no. 3, p. 703 - 716$$n3$$p703 - 716$$tInternational journal of cancer$$v134$$x0020-7136$$y2014
000127880 909CO $$ooai:inrepo02.dkfz.de:127880$$pVDB
000127880 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9c8a10405c0a6ffe7941d65e89cb7c61$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000127880 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)22e6128f8d5789c3a0c86bb0e5ca54e5$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000127880 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)119d7d540a0e6fc5734898bef4866d7f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000127880 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000127880 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000127880 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000127880 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000127880 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000127880 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000127880 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2d7958ea507b0b738619074b38ec6d54$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000127880 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000127880 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)046fd145f1008f83f6236580727bbc0f$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000127880 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000127880 9141_ $$y2014
000127880 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000127880 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000127880 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000127880 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000127880 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2015
000127880 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000127880 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000127880 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000127880 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000127880 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000127880 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000127880 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2015
000127880 9201_ $$0I:(DE-He78)F010-20160331$$kF010$$lTumorvirologie$$x0
000127880 9201_ $$0I:(DE-He78)D015-20160331$$kD015$$lTranslationale Immunologie$$x1
000127880 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x2
000127880 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x3
000127880 9201_ $$0I:(DE-He78)G340-20160331$$kG340$$lKKE Pädiatrische Onkologie$$x4
000127880 980__ $$ajournal
000127880 980__ $$aVDB
000127880 980__ $$aI:(DE-He78)F010-20160331
000127880 980__ $$aI:(DE-He78)D015-20160331
000127880 980__ $$aI:(DE-He78)B062-20160331
000127880 980__ $$aI:(DE-He78)C060-20160331
000127880 980__ $$aI:(DE-He78)G340-20160331
000127880 980__ $$aUNRESTRICTED